Medrx Co.,Ltd. Logo

Medrx Co.,Ltd.

Develops and licenses transdermal drug delivery systems for the pharmaceutical industry.

4586 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
東かがわ市西山431番地7
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Medrx Co., Ltd., established in 2002, is a pharmaceutical company focused on drug formulation development. The company specializes in creating new dosage forms and value-added medicines, with a core technological expertise in transdermal absorption and drug delivery systems. Medrx conducts research and development to create innovative pharmaceutical candidates, which it then licenses to other companies for final clinical trials, production, and commercialization. The company's primary goal is to improve global health and patient quality of life by developing medications that offer alternatives to conventional oral administration, thereby improving patient adherence and therapeutic effectiveness.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Medrx Co.,Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-08 08:33
Regulatory News Service
確認書
Japanese 8.9 KB
2025-08-08 08:31
Interim Report
半期報告書-第24期(2025/01/01-2025/12/31)
Japanese 425.8 KB
2025-06-13 08:31
Regulatory News Service
臨時報告書
Japanese 39.1 KB
2025-03-31 08:33
Regulatory News Service
内部統制報告書-第23期(2024/01/01-2024/12/31)
Japanese 23.9 KB
2025-03-31 08:32
Regulatory News Service
確認書
Japanese 8.7 KB
2025-03-31 08:32
Regulatory News Service
臨時報告書
Japanese 25.0 KB
2025-03-31 08:32
Regulatory News Service
訂正有価証券届出書(組込方式)
Japanese 271.6 KB
2025-03-31 08:31
Annual Report
有価証券報告書-第23期(2024/01/01-2024/12/31)
Japanese 1.4 MB
2025-03-28 07:31
Regulatory News Service
訂正有価証券届出書(組込方式)
Japanese 268.0 KB
2025-03-25 07:31
Prospectus
有価証券届出書(組込方式)
Japanese 409.6 KB
2024-08-09 08:01
Regulatory News Service
確認書
Japanese 8.8 KB
2024-08-09 08:00
Interim Report
半期報告書-第23期(2024/01/01-2024/12/31)
Japanese 345.0 KB
2024-05-17 08:01
Regulatory News Service
臨時報告書
Japanese 39.2 KB
2024-05-10 08:02
Regulatory News Service
確認書
Japanese 8.9 KB
2024-05-10 08:01
Quarterly Report
四半期報告書-第23期第1四半期(2024/01/01-2024/03/31)
Japanese 408.3 KB

Automate Your Workflow. Get a real-time feed of all Medrx Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Medrx Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden IMMU
Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America N/A
MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan 9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan 9227
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan 3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan 4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea 417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden MODTX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland MOC
Mural Oncology PLC Logo
Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.
N/A

Talk to a Data Expert

Have a question? We'll get back to you promptly.